Table 1.

Summary of articles for patients with acute-subacute neck pain

Authors sample size
NP status	Methodological quality of studies	Intervention $+$ Co intervention	Comparison group $+$ co intervention	Outcomes measures of interest	Clinical relevance status on timing outcomes: between groups $P$ value and effect sizes
Puentedura et al.
$n=$ 24
ANP	Level A
9/11
No for patient and care provider blinded	IG: MT1 Cx $+$ exercise
5 sessions over 2 weeks	CG: MT1 Tx $+$ exercise
5 sessions over 2 weeks	Pain (NPRS)
Functional disabilities (NDI)
(FABQ)	Yes: From 1 week to 6 months ($p<$ 0.005; SMD $=$ 2.2–2.7)
Yes: From 1 week to 6 months ($p<$ 0.05; SMD $>$ 1)
Yes: At 6 months ($p=$ 0.04; SMD $=$ 1.1)
Gonzalez-Iglesias et al.
$n=$ 45
SNP	Level A
9/11
No for patient and care provider blinded	IG : MT1 Tx
once a week over 3 weeks $+$
Electro/thermal therapy 5 times over 3 weeks	CG: Electro/thermal therapy 5 times over 3 weeks	Pain (VAS)
Functional disabilities (NPQ)
(CROM)
-Flex
-Ext
-R Rot
-L Rot
-R Lat Flex
-L Lat Flex	Yes: From post treatment to 4 weeks ($p<$ 0.001; SMD $>$ 2)
Yes: At post treatment and 2 weeks ($p<$ 0.001; SMD $=$ 2.7–2.6)
Yes: At post treatment and 2 weeks ($p<$ 0.05; SMD $=$ 2.5–1.6)
Yes: At post treatment and 2 weeks ($p<$ 0.05; SMD $=$ 1.8–1.1)
Yes: At post treatment and 2 weeks ($p<$ 0.05; SMD $=$ 1.9–2.0)
Yes: At post treatment and 2 weeks ($p<$ 0.05; SMD $=$ 2.1–1.6)
Yes: At post treatment and 2 weeks ($p<$ 0.05; SMD $=$ 2.2–1.9)
Yes: At post treatment and 2 weeks ($p<$ 0.05; SMD $=$ 2.5–1.4)
Gonzalez-Iglesias et al.
$n=$ 45
SNP	Level A
9/11
No for patient and care provider blinded	IG : MT1 Tx
once a week over 3 weeks $+$
Electro/thermal therapy 6 times over 3 weeks	CG: Electro/thermal therapy 6 times over 3 weeks	Pain (NPRS)
Functional disabilities (NPQ)
(CROM)
-Flex
-Ext
-L Lat Flex
-R Lat Flex
-L Rot
-R Rot	Yes: At 1 week ($p<$ 0.001; SMD $=$ 2.8)
Yes: At 1 week ($p<$ 0.001; SMD $=$ 2.7)
Yes: At 1 week ($p<$ 0.001; SMD $=$ 2.0)
Yes: At 1 week ($p<$ 0.001; SMD $=$ 1.5)
Yes: At 1 week ($p<$ 0.001; SMD $=$ 1.7)
Yes: At 1 week ($p<$ 0.001; SMD $=$ 1.9)
Yes: At 1 week ($p<$ 0.001; SMD $=$ 1.4)
Yes: At 1 week ($p<$ 0.001; SMD $=$ 1.4)
Nagrale et al.
$n=$ 60
ASNP	Level A
9/11
No for patient and care provider blinded	IG: MT2 (myotensive technique $+$ trigger and tender points)
3 times/week over 4 weeks for all groups	CG: MT2 (myotensive technique)	Pain (VAS)
Functional disabilities (NDI)
(CROM) Lat flex	Yes: At 2 and 4 weeks ($p<$ 0.05; SMD $=$ 1.2–1.7)
Yes: At 2 and 4 weeks ($p<$ 0.05; SMD $=$ 0.8–0.9)
Yes: At 2 and 4 weeks ($p<$ 0.05; SMD $=$ 2.0–3.8)
Blikstad and Gemmell
$n=$ 45
ASNP	Level A
9/11
No for patient and care provider blinded	IG1: MT2 (Activator trigger point therapy)
IG2:MT2 (myofascial band therapy)
1 time for all groups	CG: Sham Ultrasound (SUS)	Pain (NPRS)
Functional disabilities (CROM)	No
No
Gemmell et al.
$n=$ 45
ASNP	Level A
9/11
No for patient and care provider blinded	IG1: MT2 (Ischaemic compression)
IG2:MT2 (Trigger point pressure release)
1 time for all groups	CG: Sham Ultrasound (SUS)	Pain (VAS)
Functional disabilities
(CROM)	No
No